Asset Details
Do you wish to reserve the book?
Measuring the success of blinding in placebo-controlled trials: Should we be so quick to dismiss it?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Measuring the success of blinding in placebo-controlled trials: Should we be so quick to dismiss it?
Do you wish to request the book?
Measuring the success of blinding in placebo-controlled trials: Should we be so quick to dismiss it?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Measuring the success of blinding in placebo-controlled trials: Should we be so quick to dismiss it?
2021
Overview
What's new•Blinding in clinical trials has the potential to reduce bias.•There is a live yet underreported debate about the value of measuring blinding success.•Interpreting the success of blinding can be problematic and potentially misleading.•However, failure to report the success of blinding, if it is measured, seems like willful withholding of information that is at least potentially useful.•We suggest a middle road whereby the success of blinding be measured (where feasible) and interpreted with caution.
‘Blinding’ involves concealing knowledge of which trial participants received the interventions from participants themselves and other trial personnel throughout the trial. Blinding reduces bias arising from the beliefs and expectations of these groups. It is agreed that where possible, blinding should be attempted, for example by ensuring that experimental and control treatments look the same. However, there is a debate about if we should measure whether blinding has been successful, this manuscript will discuss this controversy, including the benefits and risks of measuring blinding within the randomised controlled trial.
Publisher
Elsevier Inc,Elsevier Limited
Subject
